Regeneron Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RGO.F | 9995.HK | ROIV | RPRX | 214450.KQ | KRYS | |
|---|---|---|---|---|---|---|
| Market cap | 72.98B | 37.47B | 27.43B | 36.62B | 2.65T | 9.52B |
| P/E (TTM) | 20.4 | 5.4 | — | 33.7 | — | 40.3 |
| Forward P/E | 16.1 | 42.4 | -22.1 | 10.9 | — | 35.9 |
| Price/book | 2.5 | 3.6 | 6.5 | 4.1 | — | 7.0 |
| Dividend yield | 0.46% | — | — | 1.51% | 1.40% | — |
| 1-year change | +42.80% | −18.32% | +103.09% | +68.66% | −53.19% | +72.79% |
| Today | −0.71% | −5.98% | +3.21% | +1.97% | −3.41% | −0.14% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All RGO.F news ›TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $980 From $960
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales ... Published on 10/21/2026 at 06:02 am EDT Regeneron's…
TD Cowen maintains Buy rating on Regeneron Pharmaceuticals, $980 price target
TD Cowen maintained their Buy rating on Regeneron Pharmaceuticals's stock with a price target of $980.00. The price target implies an upside of 21.4% from the Oct 20 close of $807.48. Strong Product Portfolio: Regeneron Pharmaceuticals has…
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $980.00 Price Target at TD Cowen
Posted by Danessa Lincoln on Oct 21st, 2026 Read Our Latest Analysis on REGN Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers,…
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen
MarketBeat Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen - TD Cowen raised Regeneron’s price target from $960 to $980 and maintained a “buy” rating, implying 21.76% upside from the reported $804.88…
Frank Rimerman Advisors LLC Acquires 876 Shares of Regeneron Pharmaceuticals, Inc. $REGN
The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This…
Regeneron Pharmaceuticals, Inc. Announces Libtayo® Recommended For EU Approval By The CHMP For Updated Dosing Regimen Across All Approved Cancer Types
Regeneron Pharmaceuticals, Inc. announced that the European Medicines Agency?s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of an... announced that the European Medicines Agency?s…
2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.
Posted by Defense World Staff on Oct 16th, 2026 First Citizens Bank & Trust Co. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the third quarter, according to the company in its most…
Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Curated Wealth Partners LLC
MarketBeat Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Curated Wealth Partners LLC - Curated Wealth Partners cut its Regeneron stake by 96.3% in the third quarter, selling 35,373 shares and retaining 1,365 shares worth…
What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report
Barchart.com
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com16
-
marketbeat.com10
-
defenseworld.net4
-
gurufocus.com4
-
moomoo.com2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 48 articles, not a forecast.